|Mr. Gary R. Maharaj||CEO, Pres & Director||1.29M||2.59M||1963|
|Mr. Timothy J. Arens||Sr. VP of Fin. & Information Technology and CFO||572k||857.12k||1967|
|Mr. Gordon S. Weber||Sr. VP of Legal, Gen. Counsel & Sec.||573.67k||N/A||1963|
|Ms. Teryl L. W. Sides||Sr. VP of Product Devel. & Chief Marketing Officer||638.67k||N/A||1970|
|Mr. Joseph J. Stich||Sr. VP and GM of HR & In Vitro Diagnostics||570.92k||501.23k||1965|
|Mr. John D. Manders||Corp. Controller & Principal Accounting Officer||N/A||N/A||1981|
|Mr. Charles W. Olson||Sr. VP of Commercial & Bus. Devel. of Medical Devices||N/A||N/A||1964|
|Mr. Gregg S. Sutton||VP of R&D - Medical Devices||N/A||N/A||1960|
Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for coronary, peripheral, neuro-vascular and structural heart, and other markets, as well as design, development, and manufacturing of interventional medical devices, primarily balloons and catheters, including drug-coated balloons for peripheral arterial disease treatment and other applications. The IVD segment designs, develops, and manufactures component products and technologies for diagnostic immunoassay, as well as molecular test and biomedical research applications. This segment offers protein stabilization reagents, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
Surmodics, Inc.’s ISS Governance QualityScore as of May 1, 2022 is 2. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 5; Compensation: 4.